Dashboard
Manage Tickers

NRSN NeuroSense Therapeutics Ltd.

Nasdaq neurosense-tx.com


$ 1.20 $ -0.03 (-2.44 %)    

Thursday, 16-Oct-2025 15:07:16 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 597.69 $ -7.52 (-1.24 %)
DIA $ 458.56 $ -4.81 (-1.04 %)
SPY $ 658.91 $ -7.98 (-1.2 %)
TLT $ 91.47 $ 0.97 (1.07 %)
GLD $ 395.16 $ 4.03 (1.03 %)
$ 1.24
$ 1.23
$ 1.19 x 12,867
$ 1.21 x 70
$ 1.20 - $ 1.24
$ 0.80 - $ 2.60
128,201
na
19.07M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

neurosense-therapeutics-announces-phase-2b-paradigm-study-results-for-primec-showing-statistically-significant-reductions-in-multiple-micrornas-linked-to-alzheimers-disease
Neurosense Therapeutics Announces Phase 2b...
10/06/2025 13:07:18

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel...

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 12:10:10

neurosense-reports-phase-2-road-trial-results-says-primec-boosts-brain-connectivity-in-alzheimers-shows-favorable-safety-profile
NeuroSense Reports Phase 2 RoAD Trial Resu...
09/10/2025 18:32:27

Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety prof...

neurosense-reports-statistically-significant-survival-benefit-in-als-phase-2b-paradigm-study-50-of-primec-patients-remain-alive
NeuroSense Reports Statistically Significa...
09/04/2025 13:12:23

NeuroSense Therapeutics Ltd. (the "Company") Reports Additional Clinical Data from its Phase 2b PARADIGM Study More tha...

neurosense-announces-500000-private-placement-of-333334-shares-at-150share
NeuroSense Announces $500,000 Private Plac...
09/04/2025 12:50:35

Financing at 40% premium to market price provides near-term bridge to anticipated milestonesCAMBRIDGE, Mass., Sept. 4, 2025 /PR...

neurosense-reports-statistically-significant-18-month-phase-2b-data-showing-primec-slows-als-progression-with-early-treatment-advantage
NeuroSense Reports Statistically Significa...
09/02/2025 12:42:16

NeuroSense Therapeutics Ltd. today announced a new analysis of 18-month data from its Phase 2b PARADIGM study of PrimeC in ALS....

neurosense-therapeutics-says-as-of-august-20-2025-20-of-people-with-als-from-the-companys-phase-2a-study-including-those-continuing-under-compassionate-use-remain-on-primec-for-more-than-55-years-having-lived-with-als-for-over-7-years-across-these-multi-year-exposures-treatment-remains-well-tolerated-with-no-new-safety-signals-observed-to-date
NeuroSense Therapeutics Says As Of August ...
08/20/2025 13:41:08

https://www.sec.gov/Archives/edgar/data/1875091/000121390025078783/ea0254016-6k_neurosense.htm

d-boral-capital-maintains-buy-on-neurosense-therapeutics-maintains-14-price-target
D. Boral Capital Maintains Buy on NeuroSen...
08/15/2025 11:15:42

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price ta...

d-boral-capital-maintains-buy-on-neurosense-therapeutics-maintains-14-price-target
D. Boral Capital Maintains Buy on NeuroSen...
07/10/2025 12:25:34

D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price ta...

why-this-nano-cap-stock-might-skyrocket-to-14-per-analyst-insights
Why This Nano-Cap Stock Might Skyrocket To...
05/12/2025 19:08:07

NeuroSense expands PrimeC production, partners with a contract organization, and targets early Canadian entry amid a $100–150 m...

this-neurosense-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-monday
This NeuroSense Therapeutics Analyst Begin...
05/12/2025 13:20:29

d-boral-capital-initiates-coverage-on-neurosense-therapeutics-with-buy-rating-announces-price-target-of-14
D. Boral Capital Initiates Coverage On Neu...
05/12/2025 11:14:35

D. Boral Capital analyst Jason Kolbert initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and ann...

neurosense-therapeutics-scales-up-production-of-primec-to-commercial-scale-following-phase-2b-paradigm-study
NeuroSense Therapeutics Scales-Up Producti...
05/07/2025 12:48:43

NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is ...

neurosense-therapeutics-outlines-phase-3-timeline-for-primec-in-als-updates-canadian-regulatory-pathway-highlights-partnership-talks-with-a-global-pharmaceutical-company-says-we-have-no-immediate-plans-for-additional-capital-raising-we-maintain-strong-relationships-with-the-investment-community-and-will-evaluate-strategic-opportunities-as-they-arise-to-support-our-needs-and-long-term-growth-objectives
NeuroSense Therapeutics Outlines Phase 3 T...
04/24/2025 13:12:30

Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership di...

neurosense-therapeutics-reports-phase-2b-microrna-data-highlighting-primecs-promise-as-a-disease-modifying-als-treatment
NeuroSense Therapeutics Reports Phase 2b M...
04/09/2025 12:32:06

New miRNA findings unveiled at the AAN, reveal key biological mechanisms behind PrimeC's clinical benefit in ALS.CAMBRIDGE,...

neurosense-therapeutics-fy-2024-gaap-eps-054-beats-060-estimate
NeuroSense Therapeutics FY 2024 GAAP EPS $...
04/07/2025 21:27:06

NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate ...

neurosense-therapeutics-to-present-data-from-primecs-phase-2b-trial-in-als-at-annual-american-academy-of-neurology-meeting
NeuroSense Therapeutics To Present Data Fr...
04/04/2025 13:12:59

Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data fro...

neurosense-regains-nasdaq-compliance
NeuroSense Regains Nasdaq Compliance
01/06/2025 14:02:05

neurosense-therapeutics-signs-binding-term-sheet-with-global-pharma-partner-to-advance-primec-for-als-includes-upfront-payment-phase-3-funding-milestone-payments-and-double-digit-royalties-definitive-agreement-expected-q1-2025
NeuroSense Therapeutics Signs Binding Term...
12/23/2024 14:06:21

neurosense-therapeutics-9-month-eps-048-up-from-055-yoy
NeuroSense Therapeutics 9-Month EPS $(0.48...
12/18/2024 15:35:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION